Search Result

Isoforms Recommended:	AChE

Results for "

hAChE

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (8) Apoptosis (1) Beta-secretase (6) Cholinesterase (ChE) (50) Dihydroorotate Dehydrogenase (1) DYRK (1) Epoxide Hydrolase (2) Ferroptosis (1) GSK-3 (3) Histamine Receptor (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Keap1-Nrf2 (1) Microtubule/Tubulin (1) Monoamine Oxidase (5) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (1) PARP (1) Phospholipase (1) Reactive Oxygen Species (2) RIP kinase (1) ROS Kinase (4) Tau Protein (4)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Inflammation/Immunology (1) Neurological Disease (47)

By Targets:

Amyloid-β (8)

Apoptosis (1)

Beta-secretase (6)

Cholinesterase (ChE) (50)

Dihydroorotate Dehydrogenase (1)

DYRK (1)

Epoxide Hydrolase (2)

Ferroptosis (1)

GSK-3 (3)

Histamine Receptor (2)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Keap1-Nrf2 (1)

Microtubule/Tubulin (1)

Monoamine Oxidase (5)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

PARP (1)

Phospholipase (1)

Reactive Oxygen Species (2)

RIP kinase (1)

ROS Kinase (4)

Tau Protein (4)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Inflammation/Immunology (1)

Neurological Disease (47)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149237

hAChE-IN-2	Cholinesterase (ChE) Tau Protein	Neurological Disease
hAChE-IN-2 is a potent *hAChE* inhibitor, with an IC₅₀ of 0.71 μM. hAChE-IN-2 can also inhibits tau-oligomerization, with an EC₅₀ of 2.21 μM. hAChE-IN-2 exhibits neuroprotective activity .

HY-155365

hAChE-IN-5	Cholinesterase (ChE) GSK-3 Amyloid-β	Neurological Disease
hAChE-IN-5 (compound 49) is a potent *hAChE* and hBuChE inhibitor with IC₅₀ values of 0.17 μM and 0.17 μM, respectively. hAChE-IN-5 shows potent GSK3β inhibition with an IC₅₀ value of 0.21 μM. hAChE-IN-5 is used as tau protein aggregation and Aβ1-42 self-aggregation inhibitor. hAChE-IN-5 can bind virtually with the PAS affecting Aβ aggregation, thus preventing Aβ-dependent neurotoxicity. hAChE-IN-5 can penetrate BBB and has the potential for multi-targeted anti-Alzheimer's agents research .

HY-155366

hAChE-IN-6	Cholinesterase (ChE) GSK-3	Neurological Disease
hAChE-IN-6 (compound 51) is a brain penetrant *AChE* inhibitor with an IC₅₀ of 0.16 μM. hAChE-IN-6 also inhibits hBuChE and GSK3β with IC₅₀ values of 0.69 μM and 0.26 μM, respectively. hAChE-IN-6 inhibits tau protein and Aβ1-42 self-aggregation, and can be used for Alzheimer's disease (AD) research .

HY-157527

hAChE-IN-7	Cholinesterase (ChE) Beta-secretase	Neurological Disease
hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on *hAChE* (IC₅₀=69.8 nM) and hBuChE (IC₅₀=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC₅₀=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .

HY-144389

hAChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of *hAChE* and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .

HY-155086

hAChE-IN-4	Cholinesterase (ChE)	Neurological Disease
hAChE-IN-4 (Compd 5d) is a potent, blood-brain barrier-permeable hAChE inhibitor with IC₅₀ of 0.25 μM. hAChE-IN-4 can be used in Alzheimer's disease research .

HY-149233

hAChE-IN-1	Cholinesterase (ChE) Tau Protein	Neurological Disease
hAChE-IN-1 (Compound 24) is a potent *hAChE* inhibitor with an IC₅₀ of 1.09 μM. hAChE-IN-1 inhibits tau-oligomerization with an EC₅₀ of 2.71 μM in cellular tau FRET assay .

HY-163514

hAChE-IN-8	Cholinesterase (ChE) DYRK	Neurological Disease
hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of *hAChE* (IC₅₀=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC₅₀=0.542 μM), and does not inhibit Dyrk1A (IC₅₀>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research .

HY-168052

hAChE-IN-9	Amyloid-β Cholinesterase (ChE)	Neurological Disease
hAChE-IN-9 (compound 7i) is a selective inhibitor of human acetylcholinesterase (hAChE) with IC₅₀ of 0.05 μM and 2.85 μM for *AChE* and BChE, respectively. hAChE-IN-9 modulates toxic Aβ oligomer forms into non-toxic ones and has antioxidant and neuroprotective effects against Aβ-induced toxicity. hAChE-IN-9 can be used for the study of Alzheimer's disease .

HY-149287

hAChE/hBACE-1-IN-1	Cholinesterase (ChE)	Neurological Disease
hAChE/hBACE-1-IN-1 (compounds 5d) is an orally active inhibitor of *hAChE* with blood-brain permeability. hAChE/hBACE-1-IN-1 inhibits *hAChE* and hBACE-1 with IC₅₀ values of 0.076 and 0.23 μM, respectively. hAChE/hBACE-1-IN-1 inhibits Aβ_1-42 aggregation and improves mouse learning and memory ability. hAChE/hBACE-1-IN-1 can be used to research in Alzheimer's disease .

HY-161512

hAChE/hBACE-1-IN-4	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against *hAChE* and hBACE-1 enzymes (hAChE, IC₅₀=0.283 μM; hBACE-1, IC₅₀=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research .

HY-155085

hAChE-IN-3	Monoamine Oxidase Amyloid-β Cholinesterase (ChE)	Neurological Disease
hAChE-IN-3 (compounds 5c) is a potent and blood-brain barrier permeable *AChE, BuChE， MAO-B-IN-1* and BACE-1 inhibitor, with IC₅₀ values of 0.44, 0.08, 5.15 and 0.38 μM, respectively. hAChE-IN-3 has antioxidant activity and metal chelating ability. In addition, hAChE-IN-3 can bind to peripheral anion sites, and affect β amyloid and reduce Alzheimer's-associated neurodegeneration. hAChE-IN-3 has the potential for the research of Alzheimer's disease .

HY-149288

hAChE/hBACE-1-IN-2	Cholinesterase (ChE) Beta-secretase Amyloid-β	Cardiovascular Disease
hAChE/hBACE-1-IN-2 is a potent, orally active, blood-brain barrier transboundary triple inhibitor of *hAChE, hBChE, and HACE-1* with IC₅₀s of 0.113 μM, 1.48 μM and 0.38 μM, respectively. hAChE/hBACE-1-IN-2 has antioxidant activity. hAChE/hBACE-1-IN-2 also inhibits Aβ1_1-42 aggregation. hAChE/hBACE-1-IN-2 can be used to study Alzheimer's disease .

HY-162127

hAChE/hBACE-1-IN-3	Cholinesterase (ChE) Beta-secretase	Neurological Disease
hAChE/hBACE-1-IN-3 (Compound 23a) is a mixed-type inhibitor of *hAChE* and hBACE-1 with IC₅₀ values of 0.32 μM and 0.39 μM, respectively, K_i values of 0.26 μM and 0.46 μM, respectively. hAChE/hBACE-1-IN-3 can penetrate the blood-brain barrier .

HY-131252

Dihydro Donepezil Dihydro E2020	Cholinesterase (ChE)	Neurological Disease
Dihydro Donepezil (Dihydro E2020) is a metabolite of Donepezil. Donepezil is a specific and potent *AChE* inhibitor with IC₅₀s of 8.12 nM and 11.6 nM for bAChE and *hAChE*, respectively .

HY-143465

BChE-IN-5	Cholinesterase (ChE)	Neurological Disease
BChE-IN-5 is a potent and selective BChE inhibitor of hBChE over hAChE with an IC₅₀ of 2.8 nM for BChE. BChE-IN-5 has the potential for the research of alzheimer’s disease .

HY-151152

AChE-IN-24	Cholinesterase (ChE)	Neurological Disease
AChE-IN-24 is a potent *AChE* inhibitor and can penetrate the BBB. AChE-IN-24 has the mighty inhibitory activity to hAChE with an IC₅₀ value of 0.053 μM. AChE-IN-24 can be used for the research of Alzheimer s disease (AD) .

HY-131971

AChE/BChE-IN-1	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-1 is a potent and brain-penetrant dual inhibitor of Acetylcholinesterase and Butyrylcholinesterase, with IC₅₀s of 1.06 and 7.3 nM for *hAChE* and hBChE, respectively. AChE/BChE-IN-1 also has antioxidant activity. AChE/BChE-IN-1 can be used for the research of Alzheimer’s disease .

HY-149817

AChE-IN-29	Cholinesterase (ChE)	Neurological Disease
AChE-IN-29, 3-OH pyrrolidine derivative, is an cholinesterase (ChE) inhibitor. AChE-IN-29 has cholinesterase inhibitory activity for hAChE, eeAChE and eqBChE with IC₅₀ values of 0.25 μM, 0.23 μM and 0.72 μM, respectively. AChE-IN-29 can be used for the research of Alzheimer's disease .

HY-146315

AChE/BChE-IN-6	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BChE-IN-6 (compound 22) is a potent dual *AChE/BChE* inhibitor with IC₅₀ values of 0.809 µM, 2.248 µM and > 100 µM for hBChE, hAChE and hMAO-B, respectively. AChE/BChE-IN-6 penetrates the blood-brain barrier (BBB). AChE/BChE-IN-6 can be used for Alzheimer’s disease (AD) research .

HY-152037

AChE/Nrf2 modulator 1	Cholinesterase (ChE) Keap1-Nrf2	Neurological Disease
AChE/Nrf2 modulator 1 is an orally active acetylcholinesterase (AChE)/nuclear factor erythroid 2-related factor 2 (Nrf2) modulator. AChE/Nrf2 modulator 1 has Nrf2 inductive activity and AChE inhibitory activity for eeAChE and hAChE with IC₅₀ values of 0.07 μM and 0.38 μM, respectively. AChE/Nrf2 modulator 1 can be used for the research of Alzheimer's disease .

HY-W047428

4-Hydroxy-3,3-dimethylcyclohexanone	Others	Others
4-Hydroxy-3,3-dimethylcyclohexanone is a key intermediate for the synthesis of hAChE inhibitor .

HY-14566

Donepezil 5+ Cited Publications E2020 free base	Cholinesterase (ChE)	Neurological Disease Cancer
Donepezil (E2020 free base) is a specific and potent *AChE* inhibitor with IC₅₀s of 8.12 nM and 11.6 nM for bovine AChE and human AChE, respectively .

HY-W049312

7-Methoxytacrine 7-MEOTA	Cholinesterase (ChE)	Neurological Disease
7-Methoxytacrine (7-MEOTA) is an inhibitor of human acetylcholinesterase (hAChE) with an IC₅₀ value of 10 μM, and can be used for the research of Alzheimer's disease (AD) .

HY-100919

Ambenonium chloride WIN 8077 chloride	Cholinesterase (ChE)	Others
Ambenonium (WIN 8077) chloride is an orally active and reversible inhibitor of Acetyicholinesterase (AChE) with high affinity. Ambenonium chloride inhibits human *AChE* with an IC₅₀ value of 0.7 nM (hAChE) .

HY-118533A

Ambenonium dichloride tetrahydrate WIN 8077 dichloride tetrahydrate	Cholinesterase (ChE)	Neurological Disease
Ambenonium (WIN 8077) dichloride tetrahydrate is an orally active and reversible inhibitor of Acetyicholinesterase (AChE) with high affinity. Ambenonium dichloride tetrahydrate inhibits human *AChE* with an IC₅₀ value of 0.7 nM (hAChE) .

HY-155620

PD10	Cholinesterase (ChE)	Neurological Disease
PD10 is an *AChE* and BuChE inhibitor (hAChE IC₅₀: 0.56 μM; eeAChE IC₅₀: 0.59 μM; eqBuChE IC₅₀: 1.06 μM). PD10 can be used for research of Alzheimer’s disease .

HY-146664

AChE/BChE-IN-4	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-4 (BMC-3) is a dual *AChE* and BChE inhibitor with IC₅₀ values of 792 nM and 2.2 nM against human AChE (hAChE) and human BChE (hBChE), respectively. AChE/BChE-IN-4 can cross the BBB .

HY-146665

AChE/BChE-IN-5	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-5 (BMC-16) is a dual *AChE* and BChE inhibitor with IC₅₀ values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. AChE/BChE-IN-5 can cross the BBB .

HY-145833A

*sEH/AChE-IN-4*	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and *AChE* (acetylcholinesterase), with IC₅₀ values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively .

HY-149212

SD-6	Cholinesterase (ChE)	Neurological Disease
SD-6 is an orally active inhibitor of *hAChE* and hBChE with IC₅₀ values of 0.907 µM and 1.579 µM, respectively. SD-6 has excellent blood-brain barrier (BBB) permeability and no neurotoxicity, which can be used for research on Alzheimer's disease .

HY-158334

NDs-IN-1	Cholinesterase (ChE) Monoamine Oxidase NO Synthase PARP p38 MAPK RIP kinase Phospholipase Indoleamine 2,3-Dioxygenase (IDO) Dihydroorotate Dehydrogenase	Neurological Disease
(Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, *hAChE* and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases .

HY-145833

*sEH/AChE-IN-3*	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and *AChE* (acetylcholinesterase), with IC₅₀ values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively .

HY-N7263

Galanthamine N-Oxide	Cholinesterase (ChE)	Neurological Disease
Galanthamine N-Oxide is an alkaloid obtained from the bulbs of Zephyranthes concolor. Galanthamine N-Oxide inhibits electric eel acetylcholinesterase (AChE) with an EC₅₀ of 26.2 μM. Galanthamine N-Oxide is a prominent inhibitor of substrate accommodation in the active site of the Torpedo californica AChE (TcAChE), hAChE and hBChE enzymes .

HY-155621

PD24	Cholinesterase (ChE)	Neurological Disease
PD24 is an *AChE* and BuChE inhibitor (hAChE IC₅₀: 1.72 μM; eeAChE IC₅₀: 1.76 μM; eqBuChE IC₅₀: 2.64 μM). PD24 also has antioxidant activity, and inhibits DPPH (IC₅₀: 28.72 μM). PD24 can be used for research of Alzheimer’s disease .

HY-155622

PD25	Cholinesterase (ChE)	Neurological Disease
PD25 is an *AChE* and BuChE inhibitor (hAChE IC₅₀: 1.58 μM; eeAChE IC₅₀: 1.63 μM; eqBuChE IC₅₀: 2.39 μM). PD25 also has antioxidant activity, and inhibits DPPH (IC₅₀: 29.55 μM). PD25 can be used for research of Alzheimer’s disease .

HY-159482

SBN-284	Cholinesterase (ChE) NOD-like Receptor (NLR)	Neurological Disease
SBN-284 (compound 3x) is a dual inhibitor of blood-brain permeable Cholinesterases and the NLRP3 inflammasome and is effective against EeAChE, hAChE and eqBChE, the IC₅₀ values of are 0.37, 0.31, 0.29 μM respectively, and the EC₅₀ of NLRP3 inflamm is 1 μM. SBN-284 can be used in Alzheimer's disease research .

HY-146312

AChE/BChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BChE/MAO-B-IN-1 (Compound 10) is a reversible and non-time-dependent *AChE, BChE* and MAO-B inhibitor with IC₅₀ values of 7.31, 0.56 and 26.1 μM for hAChE, hBChE and hMAO-B, respectively. AChE/BChE/MAO-B-IN-1 can cross the BBB and shows neuroprotective effects without cytotoxicity .

HY-149273

hBChE-IN-1	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC₅₀=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ₄₀ protein aggregation, with IC₅₀ values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research .

HY-162402

NLRP3-IN-33	Reactive Oxygen Species Cholinesterase (ChE)	Cancer
NLRP3-IN-33 (Compound 12o) is a blood-brain barrier permeable inhibitor of *AChE* and BChE, with IC₅₀ values of 1.02 μM and 7.03 μM against *hAChE* and hBChE respectively. NLRP3-IN-33 possesses antioxidant, anti-inflammatory, and metal chelating activities, making it a potential candidate for research in Alzheimer's disease (AD) .

HY-149243

BChE-IN-16	Cholinesterase (ChE)	Neurological Disease
BChE-IN-16 (compound 87) is a highly potent BChE inhibitor with an IC₅₀ of 3.8 nM for hBChE. BChE-IN-16 has low cytotoxicity, potential CNS permeability, unique adaptability and can be used in Alzheimer's disease (AD) research.

HY-157437

AChE/BChE-IN-16	Cholinesterase (ChE) Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
AChE/BChE-IN-16 (compound C7) is a potent cholinesterase (ChE) inhibitor with IC₅₀s of 30 nM and 48 nM for human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), respectively. AChE/BChE-IN-16 exhibits a remarkable capacity to safeguard PC12 cells against H₂O₂-induced apoptosis and effectively suppresses the production of reactive oxygen species (ROS) .

HY-146399

AChE/BChE-IN-9	Cholinesterase (ChE) ROS Kinase	Neurological Disease
AChE/BChE-IN-9 (Compound 7a) is a potent, orally active *AChE* and BChE inhibitor with IC₅₀ values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. AChE/BChE-IN-9 is also an efficacious antioxidant with an IC₅₀ of 57.35 μM. AChE/BChE-IN-9 is able to chelate iron and modulates aggregation of amyloid β_{1-42. AChE-IN-16 can cross the BBB} .

HY-146035

AChE-IN-14	Cholinesterase (ChE) Histamine Receptor	Neurological Disease
AChE-IN-14 (compound 5) is a potent cholinesterase inhibitor with IC₅₀s of 0.46 , 0.48, and 0.44 μM for electric eel acetylcholinesterase (eeAChE), human recombinant acetylcholinesterase (hAChE), and equine serum butyrylcholinesterase (eqBuChE), respectively. AChE-IN-14 exhibits high affinity toward human H₃ receptor (H₃R; K_i= 159.8 nM). AChE-IN-14 can be used for the research of Alzheimer’s disease .

HY-149340

PD07	Cholinesterase (ChE)	Neurological Disease
PD07 is an orally active *AChE* inhibitor (IC₅₀: 0.29 μM for hAChE). PD07 also inhibits ChEs, BACE1 (IC₅₀: 13.42 μM), and Aβ_1–42 aggregation in in vitro. PD07 is an antioxidant, and shows DPPH inhibitory activity (IC₅₀: 26.46 μM). PD07 improves memory and cognition in Scopolamine (HY-N0296)-induced amnesia rats. PD07 can be used for research of Alzheimer’s disease .

HY-158261

AChE-IN-63	Cholinesterase (ChE) Amyloid-β Beta-secretase	Neurological Disease
AChE-IN-63 (Compound 5AD) is a selective inhibitor of *hAChE* (IC₅₀=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC₅₀= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research .

HY-147659

AChE/BChE/BACE-1-IN-2	Cholinesterase (ChE) Beta-secretase ROS Kinase	Neurological Disease
AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of *AChE, BChE, and BACE-1* with IC₅₀ values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential .

HY-147658

AChE/BChE/BACE-1-IN-1	Cholinesterase (ChE) Beta-secretase ROS Kinase	Neurological Disease
AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of *AChE, BChE, and BACE-1* with IC₅₀ values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential .

HY-151562

AChE/BuChE/MAO-B-IN-1	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .

HY-150537

AChE/GSK-3β-IN-1	Cholinesterase (ChE) GSK-3 Microtubule/Tubulin ROS Kinase	Neurological Disease
AChE/GSK-3β-IN-1 (compound GT15) is a potent, dual *AChE/GSK-3β* inhibitor with IC₅₀ values of 1.2, 149.8 and 22.4 nM for hAChE , hBChE and hGSK-3β, respectively. AChE/GSK-3β-IN-1 penetrates the blood-brain barrier (BBB). AChE/GSK-3β-IN-1 has high kinase selectivity profiles for the CMGC kinase family. AChE/GSK-3β-IN-1 occupies the ATP binding site of DYRK1A. AChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. AChE/GSK-3β-IN-1 can be used for Alzheimer’s disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7263

Galanthamine N-Oxide	Alkaloids Structural Classification other families Source classification Plants	Cholinesterase (ChE)
Galanthamine N-Oxide is an alkaloid obtained from the bulbs of Zephyranthes concolor. Galanthamine N-Oxide inhibits electric eel acetylcholinesterase (AChE) with an EC₅₀ of 26.2 μM. Galanthamine N-Oxide is a prominent inhibitor of substrate accommodation in the active site of the Torpedo californica AChE (TcAChE), hAChE and hBChE enzymes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

hAChE

Inhibitors & Agonists

NaturalProducts

Natural
Products